Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vaxcyte Inc
(NQ:
PCVX
)
73.64
+3.12 (+4.42%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
694,931
Open
71.12
Bid (Size)
70.00 (20)
Ask (Size)
76.00 (1)
Prev. Close
70.52
Today's Range
70.87 - 73.68
52wk Range
44.20 - 87.71
Shares Outstanding
93,706,790
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update
August 06, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Appoints John Furey to Board of Directors
July 02, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Performance
YTD
+17.00%
+17.00%
1 Month
-9.01%
-9.01%
3 Month
+12.31%
+12.31%
6 Month
-0.67%
-0.67%
1 Year
+56.85%
+56.85%
More News
Read More
PCVX Stock Earnings: Vaxcyte Beats EPS for Q1 2024
May 08, 2024
Via
InvestorPlace
Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
May 08, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Recap: Vaxcyte Q4 Earnings
February 27, 2024
Via
Benzinga
Earnings Scheduled For February 27, 2024
February 27, 2024
Via
Benzinga
Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says
April 10, 2024
Via
Benzinga
Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference
April 02, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Oracle To Rally Around 40%? Here Are 10 Top Analyst Forecasts For Tuesday
March 12, 2024
Via
Benzinga
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants
March 04, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 27, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
February 15, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 02, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
February 01, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Announces Pricing of $750 Million Public Offering
January 30, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
January 30, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older
January 29, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Appoints Whitney Jones as Chief People Officer
January 16, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
"Top Pick for 2024": Analyst Bullish On Phathom Pharmaceuticals On Voquezna Launch In Erosive GERD, Projecting $55.6M In Sales
January 05, 2024
Via
Benzinga
Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise
January 04, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaccine Player Vaxcyte Can Potentially Disrupt Pfizer's 20-Plus-Year Near Monopoly, Says Analyst
December 07, 2023
Via
Benzinga
VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
December 04, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Appoints Jacks Lee to Board of Directors
November 28, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates
November 27, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults
November 09, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.